Exelixis (EXEL) Reports In-Line Q4 EPS, Slight Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Oppenheimer Upgrades Exelixis (EXEL) to Outperform
February 27, 2018 4:21 AM ESTOppenheimer upgraded Exelixis (NASDAQ: EXEL) from Perform to Outperform with a price target of $40.00.
Analyst Leah Rush Cann expects the company will continue to develop its commercial drugs Cabometyx & Cometriq as its partner Genetech continues to develop Cotellic. The analyst raises 2017-201 sales... More
